Status:
NOT_YET_RECRUITING
The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patients
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Conditions:
NSCLC
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to include patients with advanced or metastatic non-small cell lung cancer who are PD-L1 negative and receiving first-line immunotherapy in routine clinical practice.
Detailed Description
This study aims to include patients with advanced or metastatic non-small cell lung cancer who are PD-L1 negative and receiving first-line immunotherapy in routine clinical practice. Clinical treatmen...
Eligibility Criteria
Inclusion
- Written informed consent must be obtained before implementing any trial-related procedures;
- Aged 18-80 years;
- Wild-type EGFR/ALK;
- Patients with locally advanced (stage IIIb/IIIc), metastatic, or recurrent (stage IV) NSCLC confirmed by histology or cytology, who are not eligible for curative surgery and cannot undergo definitive radiotherapy/chemotherapy, according to the 8th edition of the TNM staging classification by the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer;
- PD-L1 negative；
- Patients receiving first-line immunotherapy (such as PD-1/PD-L1 inhibitors).
Exclusion
- The patient refused to join this study and declined follow-up.
Key Trial Info
Start Date :
July 8 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 28 2027
Estimated Enrollment :
845 Patients enrolled
Trial Details
Trial ID
NCT06496009
Start Date
July 8 2024
End Date
April 28 2027
Last Update
July 11 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.